Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, October 28 at 2:00 PM ET

Register Free →

This Sources Sought opportunity from Department Of Health And Human Services was posted on January 22, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

NIH Tetramer Core Facility

Closed
SBSS-75N93026R00006Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 541714
New
Grant
Translational Centers Using Microphysiological Systems for Infectious Diseases (U54 Clinical Trial Not Allowed)
Solicitation # RFA-AI-28-012
The National Institute of Allergy and Infectious Diseases (NIAID) has issued solicitation RFA-AI-28-012 to establish a consortium of Translational Centers Using Microphysiological Systems for Infectious Diseases (TCMID). The primary objective is to refine and validate human tissue models using Microphysiological Systems (MPS) to a level consistent with regulatory qualifications, thereby promoting their adoption by product developers and reducing reliance on laboratory animals. This initiative aligns with NIH and FDA guidance on New Approach Methodologies (NAMs) to accelerate the development of safer medical interventions by capturing human variability and patient-specific characteristics. The program is structured around an Administrative Core, a Qualification Core, and Scientific Cores, with a heavy emphasis on technical readiness, reproducibility, and regulatory acceptance. Key deliverables include the validation of assays for specific endpoints and the submission of regulatory packages. Applicants must be domestic entities, as foreign organizations and foreign subawards are strictly prohibited. Required personnel must possess deep expertise in infectious diseases, MPS platforms, bioinformatics, and FDA submission processes. Applications are due by January 29, 2027, and must be submitted via the NIH ASSIST system or approved institutional system-to-system solutions. Evaluation is based on an overall impact score considering the project's significance, the suitability of the investigators, and the quality of the institutional environment. Mandatory application components include a Data Management and Sharing Plan and a Benchmarks and Timeline PDF not exceeding six pages. Awardees must also adhere to strict cybersecurity incident reporting guidelines, notifying HHS within 48 hours of any discovery.
National Institutes Of Health

POSTED

1 day ago

DEADLINE

in 3 months
NAICS: 541714
New
Grant
Immune Tolerance Network (UM1 Clinical Trial Required)
Solicitation # RFA-AI-28-005
The National Institutes of Health, under the Department of Health and Human Services, is seeking applications through solicitation RFA-AI-28-005 to continue the Immune Tolerance Network (ITN). This cooperative agreement aims to develop tolerogenic therapies for immune-mediated disorders, specifically focusing on autoimmune diseases, allergic diseases and asthma, and the immune-mediated consequences of transplantation. The network operates through four integrated functional areas: Leadership, Clinical Operations, Core Laboratory, and Bioinformatics. Its primary objectives include designing and conducting clinical trials, performing integrated mechanistic studies, and sharing research results. Eligible applicants include small businesses and other for-profit organizations, though non-domestic entities are ineligible. Applications are evaluated based on scientific and technical merit, with a primary focus on significance and the likelihood of exerting a sustained influence on the research field. Key requirements include maintaining active registrations in SAM.gov, eRA Commons, and Grants.gov, as well as adhering to strict cybersecurity incident reporting and human subject protection protocols. The project requires a minimum effort of 3.6 person months per year for the PD/PI and mandates participation in a kick-off meeting in Bethesda, Maryland, and bi-annual steering meetings. Applications must follow specific page limits for the research strategy subsections and include detailed plans for clinical trial implementation, data management, and biorepository services.
National Institutes Of Health

POSTED

1 day ago

DEADLINE

in 3 months
NAICS: 541714
New
Federal
Pre-Award Synopsis Texas Shield
Solicitation # DARPA-SN-27-07
The Defense Advanced Research Projects Agency (DARPA), through its Biological Technologies Office (BTO), intends to enter into an agreement with The University of Texas System consortium of universities for the Texas Shield Program. This integrated research initiative, identified by solicitation number DARPA-SN-27-07 and NAICS code 541714, focuses on developing autonomous and semi-autonomous medical technologies and scalable solutions for critical medical consumables. The primary goal is to support lifesaving medical care in contested, austere, and resource-limited environments. Key technical areas of focus include autonomous medical and robotic surgical systems, casualty evacuation, artificial-blood and supply innovation, AI-enabled clinical decision support, and mass-casualty science and simulation. This notice is a pre-award synopsis and is not a request for proposals or a competitive solicitation. Interested entities are invited to submit information by November 15, 2026, to TexasShieldxBTO@darpa.mil detailing their technical expertise, integrated research infrastructure, clinical-validation capabilities, and multi-institutional coordination capacity. Additionally, respondents must describe their consortium organizational structure, commercialization capabilities, facility clearance levels, and their ability to handle Controlled Unclassified Information. The government will not reimburse any costs associated with the preparation or submission of information in response to this notice.
Defense Advanced Research Projects Agcy

POSTED

5 days ago

DEADLINE

in 25 days
NAICS: 541714
New
Federal
Q--AMPLICON SEQUENCING SERVICES
Solicitation # 140G0226Q0047
Solicitation 140G0226Q0047 is a firm-fixed-price request for a Blanket Purchase Agreement (BPA) to provide next generation amplicon sequencing services for the USGS Upper Midwest Water Science Center’s Michigan Bacteriological Research Laboratory. The scope of work includes providing all equipment, labor, travel, and materials necessary to support research on bacterial pathogens, harmful algal blooms, microbial ecology, antibiotic resistance, and microbial source tracking. Key technical requirements include the use of Illumina MiSeq or AVITI sequencing technologies and the potential for library preparation for 16S V4 amplicon sequencing. The BPA has a total not-to-exceed value of 250,000 dollars with an estimated period of performance from September 17, 2026, to September 16, 2031. The award process prioritizes non-priced factors significantly over cost, focusing on the offeror's qualifications and technical performance. Evaluation criteria include a detailed listing of on-site equipment and calibration dates, personnel experience, internal quality assurance procedures, and a technical narrative not exceeding two pages. Performance will be executed in Lansing, Michigan, with delivery terms set as FOB Destination. Administrative requirements include electronic invoicing via the Internet Payment Platform and compliance with various federal regulations, including the Buy American Act and specific security prohibitions regarding telecommunications equipment. Proposals must be submitted to the USGS OAG Denver Acquisition Branch by September 11, 2026.
Ofc Of Acquisition Grants-Denver

POSTED

5 days ago

DEADLINE

in 3 days

General Info

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)

Place of Performance

MD

Set-Aside

NONE

Documents

1

Sources Sought Notice - NIH Tetramer Core Facility SBSS-75N93026R00006

PDF, High priority: read this first4 pages · sources-sought
High

AI Contract Breakdown

Uniform Contract Format

Sign up to view the full breakdown with detailed analysis of each section.

Timeline

PhaseClosed
Posted

Sources Sought

Response Deadline

Deadline has passed

Submission Closed

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

Show more
AgencyDepartment Of Health And Human Services → National Institutes Of Health Niaid
Contacts2 people available
OfficeBETHESDA, MD, 20892, USA

Full Description

Show more

This is a Small Business Sources Sought notice. This is NOT a solicitation for proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain information regarding: (1) the availability and capability of qualified small business sources; (2) whether they are small businesses; HUBZone small businesses; service-disabled, veteran-owned small businesses; 8(a) small businesses; veteran-owned small businesses; woman-owned small businesses; or small disadvantaged businesses; and (3) their size classification relative to the North American Industry Classification System (NAICS) code for the proposed acquisition. Your responses to the information requested will assist the Government in determining the appropriate acquisition method, including whether a set-aside is possible. An organization that is not considered a small business under the applicable NAICS code should not submit a response to this notice.



Background


As a part of the research program to improve our understanding of the progression, prevention, and treatment of infectious and immune-mediated diseases, the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) is competing the continuing requirement for the NIH Major Histocompatibility Complex (MHC) Tetramer Core Facility contract (herein referred to as the NIH Tetramer Core Facility). This facility provides synthesis and distribution of soluble MHC tetramer reagents to the global research community.



Purpose and Objectives


The scope of activities to be carried out by the NIH Tetramer Core Facility Contractor are synthesis and distribution of soluble MHC-peptide tetramer and related reagents to the broader scientific community. Such reagents include, but are not limited to: mouse, non-human primate, human, and other mammalian MHC class I monomers and tetramers; custom and premade mouse, non-human primate, human, and other mammalian class II tetramers; non-classical MHC TL, Qa-1, and mammalian CD1 monomers and tetramers; CD1d and other MHC ligands; and fluorophores for tetramer detection.



Project requirements


The major functions to be carried out by the contractor are:



A. Provide a tetramer production facility


B. Provide a distribution, tracking, and reporting system of reagents produced


C. Design a NIH Tetramer Core Facility website and provide related maintenance


D. Provide Tetramer Core Facility program management



It is estimated that 9 FTEs are required to conduct these functions.



While the NIH Tetramer Core Facility is responsible for providing ligands for all premade reagents, the client is responsible for supplying ligands for custom MHC Class I and II monomer and tetramer production.



Anticipated period of performance


The Government anticipates awarding one cost-reimbursement, term (Level of Effort) type contract to fulfill the technical requirements. The period of performance will be for one year (Base Period) plus six (6) one-year options to extend the term of the contract that may be exercised by the Government unilaterally, for a total possible period of performance of seven (7) years, beginning approximately March 21, 2027. The requirement will be the delivery of 9.00 full-time equivalents (FTEs) per year, including consultant and subcontractor effort, for the Base Period (Year 1) and 9.00 FTEs per year, including consultant and subcontractor effort, for Options 1-6 (Years 2-7).



Other important considerations


None.



Capability Statement/Information Sought


Interested contractors must submit a capability statement that clearly demonstrates their experience, qualifications, and ability to perform the described effort. The capability statement shall include, at minimum, the following information:



  1. Relevant Experience: A concise summary of prior work similar in scope and complexity, including other contracts and grants. Descriptions should highlight experience supporting centralized reagent production, scientific core facilities, or immunological research services. Emphasize accomplishments and outcomes that demonstrate capability in supporting scientific workflows and client needs.
  2. Key Personnel Qualifications: A description of professional qualifications, roles, and specific experience of personnel proposed to support this effort. Highlight expertise directly related to the tasks required for this project.
  3. Resumes for Key Staff: Detailed resumes for proposed key personnel, including at minimum, the Principal Investigator and Facility Manager. Resumes should reflect education, training, and prior experience relevant to the requirements of this solicitation.
  4. Facilities, Resources and Capacity: A description of laboratory facilities, equipment, information technology systems, personnel, and other resources available to support the work. Include information on the availability and overall capacity of these resources to perform the required tasks.
  5. Demonstrated Ability to Perform: Evidence of the ability to successfully carry out the required work, highlighting operational, technical, and management capabilities. Focus on organizational competence, proven workflows, and capability to manage complex projects efficiently.
  6. Technical and Operational Capabilities: Documentation of experience and planned approaches related to the following:
    • Production, development, quality control, documentation, and distribution of MHC multimer and related immunological reagents, including client support mechanisms;

  • Development and maintenance of a secure, multi-level database to manage all tetramer reagent requests, production, tracking, and reporting activities;
  • Development and operation of a public-facing website for the NIH Tetramer Core Facility that supports both public users (clients) and internal stakeholders;
  • Technology transfer processes;

  • Implementing appropriate safety practices related to handling of biological materials, reagents, and laboratory processes;
  • Training staff and maintaining compliance with policies and standards appropriate to the scope of work.


Page Limitations


Interested qualified small business organizations should submit a tailored Capability Statement not to exceed 5 pages, excluding resumes. Capability Statements must not include links to internet web site addresses (URLs) or otherwise direct readers to alternate sources of information. Font size must be 10 to 12 points. Spacing must be no more than 15 characters per inch. Within a vertical inch, there must be no more than six lines of text. Print margins must be at least one inch on each edge of the paper. Print setup should be single sided on standard letter size paper (8.5 x 11" in the U.S., A4 in Europe). All proprietary information should be marked as such.



Required Business Information


  • DUNS.
  • Company Name.
  • Company Address.
  • Company Point of Contact, Phone and Email address
  • Current GSA Schedules and/or Government-wide Acquisition Contracts (GWACs) appropriate to this Sources Sought.
  • Do you have a Government approved accounting system? If so, please identify the agency that approved the system.
  • Type of Company (i.e., small business, 8(a), woman owned, veteran owned, etc.) as validated via the System for Award Management (SAM) located at https://sam.gov/content/home. This indication should be clearly marked on the first page of your Capability Statement (preferable placed under the eligible small business concern’s name and address).


Number of Copies


Please submit one (1) electric copy of your response as follows:



All Capability Statements sent in response to this Small Business Sources Sought notice must be submitted electronically (via e-mail) to Zachary Fetters, Contract Specialist, at zachary.fetters@nih.gov in MS Word or Adobe Portable Document Format (PDF). The email subject line must specify SBSS-75N93026R00006. Facsimile responses will not be accepted.



Common Cut-off Date


Electronically submitted tailored capability statements are due no later than 4:00 PM, EST on February 6, 2026. CAPABILITY STATEMENTS RECEIVED AFTER THIS DATE AND TIME WILL NOT BE CONSIDERED.



Disclaimer and Important Notes


This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization’s qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, a pre-solicitation synopsis and solicitation may be published at SAM.gov. However, responses to this notice will not be considered adequate responses to a solicitation.



Confidentiality


No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation(s).

More opportunities from Department Of Health And Human Services → National Institutes Of Health Niaid

Same awarding agency

NAICS: 541715
Federal
2027 NIAID DMID Omnibus Broad Agency Announcement: Development of Medical Interventions for Infectious Diseases
Solicitation # HHS-NIH-NIAID-BAA2026-1
The National Institute of Allergy and Infectious Diseases (NIAID) is soliciting proposals under Broad Agency Announcement HHS-NIH-NIAID-BAA2026-1 to advance the research and development of medical interventions for infectious diseases. This initiative focuses on three primary research areas: the development of needle-free vaccine candidates through early-phase clinical trials; the creation of safe and effective therapeutic candidates for serious infectious diseases, including those resistant to current antimicrobial therapy; and the innovation of in vitro diagnostic technology platforms capable of rapid, automated detection of a broad panel of priority viral pathogens. The program emphasizes alignment with NIH priorities regarding biosafety, biosecurity, and the use of non-animal testing methods. Proposals must be submitted electronically via the NIAID eCPS website by December 8, 2026, at 3:00 PM Eastern Time. Technical proposals are limited to 75 pages and will be evaluated by a peer review group based on technical merit, with the technical plan and personnel qualifications being of paramount consideration. Awards are not based on a common Statement of Work; instead, offerors must propose their own technical plans, milestones, and cost structures using a base and option period format. The resulting contracts will require an accounting system compliant with generally accepted accounting principles and will involve rigorous government inspection and acceptance based on the successful completion of critical milestones.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

12 days ago

DEADLINE

in about 2 months
View Details

Find Active Opportunities Like This

Get AI-powered intelligence on the opportunities still open

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS